2023 ASCO Highlights
Learn more about key Dana-Farber research studies on Prostate, Kidney, Bladder, Breast, and Ovarian Cancer.
News Releases:
- Women with Breast Cancer Shed Pounds Thanks to Telephone-Based Weight Loss Program, Clinical Trial Finds
- Breast, Rectal, Kidney and Brain Cancer Phase 3 Trials Headline Dana-Farber Research at ASCO Annual Meeting
- Study Sends Strong Signal Not to Sequence Immune Checkpoint Inhibitors in Advanced Kidney Cancer
- Clinical Trial Points to Treatment Advances for Glioma Patients for First Time in Decades
Resources:
ASCO 2023: Glioma Research Presented by Patrick Wen, MD
The first phase 3 clinical trial of a molecularly targeted therapy for low grade IDH-mutant glioma showed positive results and opens the door to new possibilities for patients.
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD
We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.
ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD
Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.
ASCO 2023: Prostate Cancer Research Presented by Praful Ravi, MB BCHIR, MRCP
ICECAP collaboration was the largest study looking at the prognostic value of PSA nadir in localized prostate cancer, finding a PSA level of less than 0.1 could provide an early prognosis signal.
ASCO 2023: Treating NUT Carcinoma Research Presented by Jia Luo, MD
Dana-Farber's Jia Luo, MD, details on findings from the NUT Carcinoma Registry on initial chemotherapy for locally advanced and metastatic disease.
ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD
Encouraging anti-tumor activity for patients with metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGF-beta inhibitor BCA101 w/pembrolizumab.
ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD
Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.
ASCO 2023: Bladder Cancer Highlights Presented By Charlene Mantia, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2023.
ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2023.
ASCO 2023: Prostate Cancer Highlights Presented By Jacob Berchuck, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2023.
